Kamada Ltd. (KMDA) - רווח נקי למניה (EPS TTM)

Kamada Ltd. (KMDA) is scaling its biopharmaceutical business through global B2B agreements, optimizing its plant capacity utilization. Growth is driven by plasma access and the success of new developments for rare pathologies. This rolling 12-month EPS chart demonstrates the actual stock yield, where 0.43 describes the current status of the metric. A flawless global image and government contracts confirm the high quality of the brand's products.

Investors utilize this metric to assess the business's actual ability to generate earnings per share, stripped of one-off factors over a trailing twelve-month period. Driven by the Israeli management's expertise in the plasma sector and capacity optimization, the TTM net income per share for Kamada Ltd. (KMDA) serves as a precise indicator of capital management efficiency within a narrow niche, establishing the asset's status as fundamentally resilient.